Data for R&D

同乐城TLC官网 www.zhaoxuefen.com  

 

How to maximize data’s potential in drug and device research & development.

 

Data for R&D, Thursday 10 October 2019

08:00

Registration & Breakfast

Plenary Keynotes

Ed Simcox
08:40

Data innovation in the American government: how the HHS effectively leverages data, technology and innovation to improve lives

Gianluca Pettiti
09:00

Automating data: how AI and automation will impact the use of data applied to lab interconnectivity and sample analysis

Arpa Garay
09:20

C-level / SVP Pharma Panel

Data strategies for R&D, addressing the importance of privacy, leveraging new technology and analytics for product commercialization, and integrating data into pharma companies.
10:20

Networking Coffee Break

Oncology

Jane Fang
Data for R&D
11:00

Integrating EMR data for cancer drug development: how to develop cancer treatments of scale by integrating gene panels and EMR records for patient recruitment data

James Broach
Data for R&D
11:20

Targeting groups of cancer genes in a pathway: how to identify driver alterations within pathways and choose a targetable alteration to optimize cancer therapy

Andrey Loboda
Data for R&D
11:40

Cancer data mining: how to leverage the recent influx of complex molecular data in immune-oncology to understand tumor- immune interaction, identify new targets, and develop novel biomarkers

Panna Sharma
Data for R&D
12:00

Creating value through large genomic data sets: how human guided machine learning is used to analyze large patient data sets and develop novel oncology therapies

12:20

Networking Lunch

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)

13:40

Roundtable: AI integration: how incorporating AI into all phases of drug development from target discovery, to the recovery of failed projects is transforming pharma

Jill Bonjean
13:40

Roundtable: Cross-sector networking for rare diseases: exploring vital data from AI, devices, research, and IT related to rare disease patients

Jill Bonjean, Corporate Relations Advisor, Rare Disease International
Pamela Mace, President, Fibromuscular Dysplasia Society of America
Stephen Groft
13:40

Roundtable: Diversity in clinical research: how to use data to increase ethnic, racial, and gender diversity in clinical trials to improve outcomes for patients of all backgrounds

Stephen Groft, Senior Advisor To The Director, Ncats, NIH
Monika Schneider
13:40

Roundtable: Incentivizing orphan drug innovation: how to motivate companies to develop orphan drugs through changes to reimbursement and tax incentives

Stephan Schuster
13:40

Roundtable: Microbiomes as indicators of health: how the surrounding environment can impact human health, and an examination of the data supporting this as evidence

Fergal Mccaffery
13:40

Roundtable: Mitigating the risk of mobile healthcare

How to secure data with the influx of healthcare apps and the move to patient interaction via mobile devices by conducting more frequent HIPAA security checks and penetration-testing / vulnerability-assessments of IT systems.
Yizhen Dong
13:40

Roundtable: Multidisciplinary approaches: how to apply digital data to drug discovery, use new technology for data mining, and utilize machine learning

Jenny Royle
13:40

Roundtable: The impact of safety data collection: how to treat disease and improve the quality of life for patients while properly characterizing the effects of the drug

Eric Weintraub
13:40

Roundtable: Using data to develop innovative telemedicine programs: sharing ideas for the creation and implementation of telehealth programs

Pricing & Reimbursement

Redouane Soualmi
Data for R&D
14:50

Early pricing decisions: how to address drug pricing concerns prior to regulatory approval

Redouane Soualmi, Head Of Market Access And Government Affairs Nwa, Boehringer Ingelheim
Xin Chen
Data for R&D
15:10

Value based assessment: how Real-World Evidence (RWE) can improve estimates of actual drug use and costs, and increase transparency in health outcomes

More information soon.
Allen King
Data for R&D
15:30

Reimbursement for gene therapy: how creating outcomes-based agreements incites a greater need to collect data to ensure patient access to treatments

Networking Coffee Break

Plenary Keynotes

Data Democratization

17:30

Closing remarks followed by networking drinks reception

More information soon.
last published: 23/Aug/19 20:05

Data for R&D, Friday 11 October 2019

08:00

Registration & Breakfast

Plenary Keynotes

Debbie Profit
09:00

Collaboration for innovation: a case study discussion about Project Baseline’s digitally innovative, patient-centered approach to challenges with data fragmentation within research programs

10:20

Networking coffee break

Rare Diseases

Monica Weldon
Data for R&D
11:00

Real world data for rare diseases: how to make drug development more feasible for rare diseases and improve regulatory decision making

More information soon.
Xin Du
Data for R&D
11:20

FDA updates for rare disease data: how to approach rare disease data and make company-wide updates to improve data submission

Data for R&D
11:40

Data sharing for rare diseases: assessing the importance of data sharing for rare disease product development

12:20

Networking Lunch

June Lee
13:40

Roundtable: AI for therapeutics: how to apply automation and machine learning to treatments and encourage the use of AI beyond drug discovery

Amelia Anderson
13:40

Roundtable: Computational molecular dynamics: small molecule data approaches for modifying drugs and identifying targets

Manuel Corpas
13:40

Roundtable: Genomic interpretation for accurate diagnoses: how to simplify the process of genetic screening from sample to report interpretation

Nadeem Sarwar
13:40

Roundtable: Genomics in drug discovery: how to expedite the drug development through genomics and structural/cultural changes

Eve Bukowski
13:40

Roundtable: Strategic data presentations for government support

How to engage government officials by shifting from the use of quantitative data (hard numbers) to qualitative data (telling the patient story) in your presentation.
Hollie Schmidt

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30 minutes – attendees can select two roundtables to attend)

Non-Clinical Data

Sàndor Szalma
Data for R&D
14:50

Translational bioinformatics: how to generate translational insights by integrating and validating public/internal data through a combination of statistical and machine learning methods

More information soon.
Data for R&D
15:10

RWE for regulatory applications

How to present data in such a manner as to lower time and costs of product approvals, identify new uses for existing products, and improve clinical practices for the use of drugs and medical devices.
15:30

End of Conference

last published: 23/Aug/19 20:05

 

Contact us

To sponsor or exhibit contact:
André Singer
t/ 646.619.1797 

andre.singer@www.zhaoxuefen.com


To speak:
Anna Bagley
t/ 646 619-1803 

anna.bagley@www.zhaoxuefen.com